MX2016004285A - Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. - Google Patents
Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.Info
- Publication number
- MX2016004285A MX2016004285A MX2016004285A MX2016004285A MX2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A MX 2016004285 A MX2016004285 A MX 2016004285A
- Authority
- MX
- Mexico
- Prior art keywords
- gamma
- interferon
- composition
- drug
- loaded
- Prior art date
Links
- 102000008070 Interferon-gamma Human genes 0.000 title abstract 4
- 108010074328 Interferon-gamma Proteins 0.000 title abstract 4
- 229960003130 interferon gamma Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan las composiciones y métodos para tratamientos de cáncer, la metodología implica, por ejemplo, administrar a un paciente con cáncer una primera composición que comprende una pluralidad de minicélulas intactas derivadas de bacterias o células bacterianas eliminadas intactas, cada una de las cuales abarca un agente anti-neoplásico y porta un ligando inespecífico en la superficie, el ligando tiene especificidad para un componente de la célula de mamífero y una segunda composición que comprende interferón-gamma (IFN-gamma) o un agente que incrementa la expresión de IFN-gamma en el sujeto; las composiciones incluyen la primera composición y la segunda composición como se describe, opcionalmente con agentes anti-neoplásicos adicionales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887258P | 2013-10-04 | 2013-10-04 | |
| PCT/IB2014/002824 WO2015049589A1 (en) | 2013-10-04 | 2014-10-03 | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004285A true MX2016004285A (es) | 2016-07-08 |
| MX384311B MX384311B (es) | 2025-03-14 |
Family
ID=52777107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004285A MX384311B (es) | 2013-10-04 | 2014-10-03 | Combinación con minicélulas dirigidas por ligando, biespecíficas, cargadas con fármacos e interferón-gamma para usarse en el tratamiento de tumores. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9731011B2 (es) |
| EP (1) | EP3052122B1 (es) |
| JP (1) | JP6538031B2 (es) |
| KR (1) | KR102433719B1 (es) |
| CN (1) | CN105658233B (es) |
| AP (1) | AP2016009153A0 (es) |
| AU (1) | AU2014330895B2 (es) |
| CA (1) | CA2926161C (es) |
| EA (1) | EA032740B1 (es) |
| IL (1) | IL244851B (es) |
| MX (1) | MX384311B (es) |
| NZ (1) | NZ718148A (es) |
| SG (1) | SG11201602429QA (es) |
| TW (1) | TWI737576B (es) |
| WO (1) | WO2015049589A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201602429QA (en) * | 2013-10-04 | 2016-04-28 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
| CA3211718A1 (en) * | 2014-10-03 | 2016-04-07 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| JP7213798B2 (ja) * | 2016-10-06 | 2023-01-27 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 核酸アジュバントを送達するための細菌ミニ細胞およびその使用方法 |
| CA3069523A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| KR102869944B1 (ko) | 2018-07-11 | 2025-10-15 | 액팀 테라퓨틱스, 인코퍼레이티드 | 조작된 면역자극성 박테리아 균주 및 이의 용도 |
| WO2020021437A1 (en) * | 2018-07-23 | 2020-01-30 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived minicells and methods of using the same |
| AU2020205040A1 (en) | 2019-01-04 | 2021-08-12 | Engeneic Molecular Delivery Pty Ltd | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| US12357687B2 (en) | 2020-03-24 | 2025-07-15 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same |
| EP4126031A4 (en) * | 2020-03-24 | 2024-03-27 | EnGeneIC Molecular Delivery Pty Ltd. | COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRUS INFECTIONS, INCLUDING CORONAVIRUS INFECTIONS, AND METHODS OF USE THEREOF |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2315067B (en) | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
| CA2372782A1 (en) | 1999-05-11 | 2000-11-16 | Wing Cheung | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| JP2003513681A (ja) * | 1999-11-12 | 2003-04-15 | マキシゲン・ホールディングス・リミテッド | インターフェロンガンマ・コンジュゲート |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| AU2002347426B2 (en) | 2001-10-15 | 2007-05-10 | Engeneic Molecular Delivery Pty Ltd | Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo |
| EP1594547A2 (en) * | 2003-02-14 | 2005-11-16 | University Of South Florida Research Foundation, Inc. | Chitosan-microparticles for ifn gene delivery |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| PL1694361T3 (pl) | 2003-12-09 | 2011-08-31 | Engeneic Molecular Delivery Pty Ltd | Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii |
| SG169373A1 (en) * | 2004-02-02 | 2011-03-30 | Engeneic Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP2386640B1 (en) * | 2004-08-26 | 2015-01-28 | EnGeneIC Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| CA2803995C (en) | 2004-08-26 | 2014-06-10 | Engeneic Molecular Delivery Pty Ltd. | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| US7840438B2 (en) * | 2005-07-29 | 2010-11-23 | Yahoo! Inc. | System and method for discounting of historical click through data for multiple versions of an advertisement |
| CA2658058C (en) * | 2006-06-23 | 2016-08-23 | Engeneic Molecular Delivery Pty Ltd. | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| ES2626179T3 (es) | 2007-03-30 | 2017-07-24 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas de origen bacteriano que encierran ARN regulador |
| CA2818713C (en) | 2010-12-02 | 2019-03-26 | Nerviano Medical Sciences S.R.L. | Process for the preparation of morpholinyl anthracycline derivatives |
| SG11201403062YA (en) * | 2011-12-13 | 2014-07-30 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| CN113577260A (zh) * | 2012-10-02 | 2021-11-02 | 瓦克星治疗有限责任公司 | 免疫调节性小细胞及使用方法 |
| SG11201602429QA (en) * | 2013-10-04 | 2016-04-28 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
-
2014
- 2014-10-03 SG SG11201602429QA patent/SG11201602429QA/en unknown
- 2014-10-03 CA CA2926161A patent/CA2926161C/en active Active
- 2014-10-03 US US14/506,138 patent/US9731011B2/en active Active
- 2014-10-03 CN CN201480054853.1A patent/CN105658233B/zh active Active
- 2014-10-03 WO PCT/IB2014/002824 patent/WO2015049589A1/en not_active Ceased
- 2014-10-03 AP AP2016009153A patent/AP2016009153A0/en unknown
- 2014-10-03 MX MX2016004285A patent/MX384311B/es unknown
- 2014-10-03 TW TW103134613A patent/TWI737576B/zh active
- 2014-10-03 EP EP14851383.1A patent/EP3052122B1/en active Active
- 2014-10-03 NZ NZ718148A patent/NZ718148A/en unknown
- 2014-10-03 JP JP2016519841A patent/JP6538031B2/ja active Active
- 2014-10-03 AU AU2014330895A patent/AU2014330895B2/en active Active
- 2014-10-03 EA EA201690680A patent/EA032740B1/ru unknown
- 2014-10-03 KR KR1020167010107A patent/KR102433719B1/ko active Active
-
2016
- 2016-03-31 IL IL244851A patent/IL244851B/en active IP Right Grant
-
2017
- 2017-07-28 US US15/663,562 patent/US10500277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105658233A (zh) | 2016-06-08 |
| EA201690680A1 (ru) | 2016-07-29 |
| IL244851A0 (en) | 2016-05-31 |
| IL244851B (en) | 2020-04-30 |
| EP3052122A1 (en) | 2016-08-10 |
| SG11201602429QA (en) | 2016-04-28 |
| CA2926161C (en) | 2023-03-14 |
| NZ718148A (en) | 2022-02-25 |
| CA2926161A1 (en) | 2015-04-09 |
| CN105658233B (zh) | 2020-09-04 |
| AU2014330895A1 (en) | 2016-04-14 |
| BR112016007100A2 (pt) | 2017-08-01 |
| EP3052122A4 (en) | 2017-05-17 |
| TW201601748A (zh) | 2016-01-16 |
| JP2016532639A (ja) | 2016-10-20 |
| US20170326235A1 (en) | 2017-11-16 |
| US10500277B2 (en) | 2019-12-10 |
| KR20160058885A (ko) | 2016-05-25 |
| JP6538031B2 (ja) | 2019-07-03 |
| TWI737576B (zh) | 2021-09-01 |
| AP2016009153A0 (en) | 2016-04-30 |
| WO2015049589A1 (en) | 2015-04-09 |
| AU2014330895B2 (en) | 2019-08-15 |
| MX384311B (es) | 2025-03-14 |
| EA032740B1 (ru) | 2019-07-31 |
| EP3052122B1 (en) | 2024-09-25 |
| US20150098897A1 (en) | 2015-04-09 |
| KR102433719B1 (ko) | 2022-08-17 |
| US9731011B2 (en) | 2017-08-15 |
| HK1223281A1 (en) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004285A (es) | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| MX2015000438A (es) | Manejo de toxicidad para actividad antitumoral de cars. | |
| MX2017017079A (es) | Sistema de administracion dirigida de principio activo celular. | |
| CO6670568A2 (es) | Métodos de terapia combinada para tratar enfermedades profilerativas | |
| SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| CL2017001943A1 (es) | Terapias de combinación para el tratamiento de cánceres | |
| UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
| CL2016002312A1 (es) | Modulador del receptor de andrógeno y usos de este. | |
| MX2015003643A (es) | Metodo para tratar el cancer. | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| CR20120528A (es) | Métodos para tratar el cáncer | |
| MX375838B (es) | Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas. | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| MX2017007256A (es) | Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer. | |
| CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
| AR094026A1 (es) | Metodo para activar la celula t helper | |
| MX2014010713A (es) | Activacion de procaspasa 3 mediante terapia de combinacion. | |
| MX2019014800A (es) | Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso. | |
| MX2014010714A (es) | Terapia de combinacion de procaspasa para gliobastoma. |